CRNX vs AKRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRNX Captures Institutional Edge (2โ1 Pillars ยท 3โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crinetics Pharmaceuticals, Inc. (CRNX) driven by superior Momentum & Technical, Options & Structure while AKRO counters with relative strength in Growth & Margin. Fundamentally, CRNX trades at N/M Forward P/E with -527.4% operating margin (+2336.3% YoY revenue) versus AKRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRNX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRNX | AKRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.0B | $4.5B | Larger Scale | CRNX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +2336.3% | +0.0% | Higher Growth | CRNX |
| Operating Margin (TTM) Profitability | -527.4% | 0.0% | Higher Margin | AKRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -42.4% | -34.5% | Higher ROE | AKRO |
| 52-Week Range Position Momentum | 100% ($30โ$85) | 90% ($21โ$58) | Stronger Trend | CRNX |
| Beta / 30D Volatility Risk Regime | 0.29ฮฒ ยท 2% Vol | 0.90ฮฒ ยท 2% Vol | Lower Realized Risk | Tie |
| Unified Institutional Score Composite Signal | 46.8 / 100 (HOLD) | 60.0 / 100 (BUY) | Higher Composite | AKRO |